Concepedia

Pascal Deschatelets

PD

Statistics

Publications

15

Citations

1.9K

H-Index

13

Active since

2001

Affiliations

Apellis Pharmaceuticals (United States)(Current)

Prince of Wales Hospital

Duke University

Chinese University of Hong Kong

Songklanagarind Hospital

Pascal Deschatelets is an author at Apellis Pharmaceuticals (United States) specializing in medicine, immune regulation, and humoral immunity.

ORCID

Top concepts

Publications per year

2001–2023

15

Publications

15

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration

David Liao, F Grossi, Delphine El Mehdi et al. · Ophthalmology · 2019 · 491 citations · Full text

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

, , +4

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, Jeff Szer, Ilene C. Weitz et al. · New England Journal of Medicine · 2021 · 356 citations

Designing a polyvalent inhibitor of anthrax toxin

Michaël Mourez, Ravi S. Kane, Jeremy Mogridge et al. · Nature Biotechnology · 2001 · 270 citations

, , +2

<scp>C3</scp> inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Carlos de Castro, F Grossi, Ilene C. Weitz et al. · American Journal of Hematology · 2020 · 97 citations · Full text

1–5 of 15